Search

Your search keyword '"Yao, Huilan"' showing total 49 results

Search Constraints

Start Over You searched for: Author "Yao, Huilan" Remove constraint Author: "Yao, Huilan"
49 results on '"Yao, Huilan"'

Search Results

4. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.

5. Numerical Study of Stern Vibration of a Self-Propulsion Ship in Propeller Induced Pressure Fluctuation

9. Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma

10. Flow physics behind the wake of a flapping hydrofoil turbine near a wall.

14. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers

16. S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

18. Data from Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non–Muscle Invasive Murine Bladder Cancer

19. Supplementary Table from Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non–Muscle Invasive Murine Bladder Cancer

20. Supplementary Figure from Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non–Muscle Invasive Murine Bladder Cancer

21. Correction: Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non–Muscle Invasive Murine Bladder Cancer

25. Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

29. Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non–Muscle Invasive Murine Bladder Cancer

31. A cross‐sectional observational study on the level of diabetes knowledge and related influencing factors among orthopaedic nurses.

32. Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (10.1038/s41375- 021-01273-7):SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (Leukemia, (2021), 35, 9, (2698-2702), 10.1038/s41375-021-01273-7)

33. Abstract PS12-23: Development of H3B-6545, a first-in-class oral selective ER covalent antagonist (SERCA), for the treatment of ERaWTand ERaMUTbreast cancer

35. Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

36. Molecular characterization and monitoring of patient ctDNA in phase I study of H3B-6545 in ER+ MBC.

37. Coupling multiplex pre-amplification and droplet digital PCR for longitudinal monitoring ofESR1andPIK3CAmutations from plasma cell-free DNA

39. Abstract 1185: H3B-8800, a novel orally available SF3b modulator, shows preclinical efficacy across spliceosome mutant cancers

48. Up-Regulation of Mitochondrial Activity and Acquirement of Brown Adipose Tissue-Like Property in the White Adipose Tissue of Fsp27 Deficient Mice

49. Up-Regulation of Mitochondrial Activity and Acquirement of Brown Adipose Tissue-Like Property in the White Adipose Tissue of Fsp27 Deficient Mice

Catalog

Books, media, physical & digital resources